Innovation Society Online
July 2009 -- Ventures in Medicine: Innovations in Cardiology and Beyond
Ventures in Medicine:
Innovations in Cardiology and Beyond
Ted McClusky
Chief Medical Officer and VP of Clinical, Aviir, Inc.
Board Member, Sand Hill Angels
Ted McCluskey, MD/PhD is Chief Medical Officer and VP of Clinical at Aviir, Inc., a cardiovascular diagnostic company in Palo Alto. Aviir is a venture-funded biotechnology company developing cutting edge, convenient diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. Ted was trained as an interventional cardiologist. In addition to being an MD, he has a PhD in Pharmacology. Ted is also a Board Director of Sand Hill Angels, where he manages the education process.
Prior to Aviir, Ted spent four years at Scios (a Johnson&Johnson Company) where he oversaw cardiovascular clinical development, including VEGF-121 and their lead product Natrecor. Prior to Scios, Ted was at Genentech for 8 years, overseeing clinical research on cardiovascular applications for TNKase, Bosentan, CathFlo Activase and for the recently approved anti-angiogenic ophthalmic agent Lucentis. He led the clinical development for the cardiovascular application of VEGF (vascular endothelial growth factor) by direct intra-coronary injection and has had extensive experience in both in-licensing and out-licensing projects.
Join us as Ted shares his experiences and insights in this rich innovation journey in medicine.
Bring your own perspectives and questions, and see you there!
Program Schedule
6:00: Arrival and networking
6:45: Community buffet dinner
7:10: Appetizer Story
7:15: Introductions
7:30: Feature Presentation
8:30: Showing Up
9:30: Closing
Innovations in Cardiology and Beyond
Ted McClusky
Chief Medical Officer and VP of Clinical, Aviir, Inc.
Board Member, Sand Hill Angels
Ted McCluskey, MD/PhD is Chief Medical Officer and VP of Clinical at Aviir, Inc., a cardiovascular diagnostic company in Palo Alto. Aviir is a venture-funded biotechnology company developing cutting edge, convenient diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. Ted was trained as an interventional cardiologist. In addition to being an MD, he has a PhD in Pharmacology. Ted is also a Board Director of Sand Hill Angels, where he manages the education process.
Prior to Aviir, Ted spent four years at Scios (a Johnson&Johnson Company) where he oversaw cardiovascular clinical development, including VEGF-121 and their lead product Natrecor. Prior to Scios, Ted was at Genentech for 8 years, overseeing clinical research on cardiovascular applications for TNKase, Bosentan, CathFlo Activase and for the recently approved anti-angiogenic ophthalmic agent Lucentis. He led the clinical development for the cardiovascular application of VEGF (vascular endothelial growth factor) by direct intra-coronary injection and has had extensive experience in both in-licensing and out-licensing projects.
Join us as Ted shares his experiences and insights in this rich innovation journey in medicine.
Bring your own perspectives and questions, and see you there!
Program Schedule
6:00: Arrival and networking
6:45: Community buffet dinner
7:10: Appetizer Story
7:15: Introductions
7:30: Feature Presentation
8:30: Showing Up
9:30: Closing
Replies to This Discussion
-
Permalink Reply by Sue Klein Lebeck on -
If you missed this technically and medically inspiring evening,
check out the informal video series:
http://www.sviisociety.com/video/svii-ted-mccluskey-avirr-inc
Video series provided courtesy of Bill Daul.
Thanks Bill!
© 2009 Created by Vitaly on Ning. Create a Ning Network!
